Funding used to accelerate vascular treatment development ahead of next year’s clinical trials in humans. Elastrin Therapeutics, a privately held …
Continue reading “Kizoo portfolio company Elastrin Therapeutics closes $10 million funding round”
Kizoo provides seed funding for Elastrin Therapeutics to develop ground-breaking new technology capable of reversing tissue and organ calcification. It …
Continue reading “Elastrin limbers up for success with Kizoo funding boost”
Underdog Pharmaceuticals’ success means its name needs to change. Enter Cyclarity, which takes up residence in state-of-the-art labs at the …
Continue reading “Underdog becomes Cyclarity – and moves to the Buck Institute”
Berlin will play host to a summit showcasing the research and developments in rejuvenation biotech. The Rejuvenation Startup Summit (Berlin, 14-15 October …
Continue reading “Join the largest gathering of longevity CEOs – in person”
Longevity was one of the most talked about industries on the streets of Davos during this year’s World Economic Forum …
Continue reading “Longevity takes over Davos – and has Gstaad in its sights”
Networking event for rejuvenation startups, longevity investors and translational researchers aims to accelerate the development of the rejuvenation biotech industry. …
Continue reading “World’s first Rejuvenation Startup Summit is announced”
Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’ enzyme therapy pipeline towards the …
Continue reading “Revel announces $8.4m for repairing-based approaches to reversing aging”
Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged …
Underdog Pharmaceuticals, a key investment of rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Michael Greve’s Kizoo …
Continue reading “SENS spin-out Underdog closes $10m financing round”
